NBIX News and Press, Neurocrine Biosciences Inc. From 01/03/22

Neurocrine Biosciences to Present at the 40th Annual J.P. Morgan Healthcare Conference PR Newswire SAN DIEGO , Jan. 3, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the virtual 40 th Annual J.P. Morgan Healthcare Confer...

Neurocrine Biosciences (NBIX +2.4%) has gained for the third consecutive session after the company disclosed that its Phase 3 trial to assess Ingrezza (valbenazine) in chorea associated with Huntington's Disease met the primary endpoint. After valbenazine showed a statistically significa...

Neuorocrine Biosciences' (NASDAQ:NBIX) Ingrezza (valbenazine) met its primary endpoint in a phase 3 trial to treat chorea associated with Huntington's Disease. Shares are up 3% in after-hours trading. Patients in the valbenazine arm achieved a statistically significant mean reductio...

Neurocrine Biosciences Announces Positive Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease - Highly Statistically Significant Reduction in Chorea Movements (p < 0.0001) as Measured by the Unified Huntington's Disease Rating...

Although the Healthcare sector is having a positive year in absolute terms, that isn't the case in relative terms. Biotech stocks are having a difficult year, in spite of many of those trading at dirt-cheap valuations that don't even reflect the cash they have in-hand. It's very l...

Neurocrine Biosciences (NBIX -1.8%) announced the appointment of Jude Onyia as the company’s Chief Scientific Officer. A 25-year veteran in the pharmaceutical industry, Dr. Onyia last served as Chief Scientific Officer at Capsida Biotherapeutics. Before that, he worked at Eli Lilly (NY...

Neurocrine Biosciences Appoints Jude Onyia, Ph.D., as Chief Scientific Officer PR Newswire SAN DIEGO , Nov. 30, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that Jude Onyia , Ph.D., has joined the company's executive m...

Neurocrine Biosciences (NASDAQ:NBIX) and Sosei Group Corporation (OTCPK:SOLTF) (Sosei Heptares) announced an agreement for strategic collaboration and licensing in the development of muscarinic receptor agonists for neuropsychiatric disorders such as schizophrenia and dementia. Per the d...

Neurocrine Biosciences and Sosei Heptares Announce Collaboration to Develop Novel Muscarinic Receptor Agonists for Schizophrenia and Other Neuropsychiatric Disorders Neurocrine Biosciences anticipates initiating a Phase 2 study with the selective M4 agonist HTL-0016878 in schizo...

BMO has initiated shares of Neurocrine Biosciences (NASDAQ:NBIX) with an underperform rating, saying that sales of the company's tardive dyskinesia drug Ingrezza (valbenazine) are unlikely to exceed $2B. Analyst Evan Seigerman writes that pricing pressure on the drug is likely to increase due...